The ESR1 mutated metastatic breast cancer diagnostics market is set to experience robust growth in the coming decade. According to recent projections, the market is expected to expand from USD 63.4 million in 2024 to USD 89.6 million by 2034, reflecting a year-on-year (y-o-y) growth rate of 4.0%. Over the forecast period, demand for ESR1 mutated metastatic breast cancer diagnostics is anticipated to rise at a compound annual growth rate (CAGR) of 3.7%.
This sustained growth is attributed to increasing awareness and advancements in diagnostic technologies, coupled with the rising prevalence of metastatic breast cancer cases linked to ESR1 mutations. As more healthcare providers prioritize precision medicine, the need for accurate and early detection methods will further drive market expansion.
One of the key drivers of growth in the ESR1 mutated metastatic breast cancer diagnostics market is the increasing prevalence of breast cancer. Breast cancer is one of the most common types of cancer, affecting millions of people worldwide. According to the World Health Organization (WHO), breast cancer is the most common cancer among women globally, with an estimated 2.3 million new cases diagnosed in 2020 alone. As breast cancer continues to be a major public health concern, the demand for advanced diagnostic tools like ESR1 mutated metastatic breast cancer diagnostics is expected to rise.
Advancements in diagnostic technology have also contributed to the growth of the ESR1 mutated metastatic breast cancer diagnostics market. In recent years, there have been significant advances in the field of cancer diagnostics, including the development of advanced imaging techniques and molecular diagnostic tests. These advancements have made it possible for medical professionals to identify ESR1 mutations more accurately and efficiently, allowing for earlier diagnosis and more personalized treatment options.
Another factor driving growth in the ESR1 mutated metastatic breast cancer diagnostics market is the increasing awareness of ESR1 mutations among medical professionals and patients. As medical research continues to uncover new information about breast cancer mutations, more healthcare providers are becoming aware of the importance of ESR1 testing. This increased awareness has led to greater demand for ESR1 mutated metastatic breast cancer diagnostics, as well as increased funding for research and development in this area.
Key Takeaways:
- The global ESR1 mutated metastatic breast cancer diagnostics market is expected to grow with an 11% CAGR from 2023 to 2033.
- By end user, diagnostic centres are expected to hold 47% of the market share in 2023 for ESR1 mutated metastatic breast cancer diagnostics market.
- North America is expected to possess a 45% market share for ESR1 mutated metastatic breast cancer diagnostics market in 2023.
- Europe ESR1 mutated metastatic breast cancer diagnostics market size is expected to possess a 40% market share in 2023.
Competitive Landscape:
Key players in the ESR1 mutated metastatic breast cancer diagnostics are Berlin-Chemie, Pfizer, Sanofi, G1 Therapeutics, Inc., Sun Pharma Advanced Research Company, Zenopharm, Arvinas, Sermonix Pharmaceuticals, Roche, AstraZeneca, Novartis, Zentalis Pharmaceuticals, Olema Pharmaceuticals
- Sanofi has developed a targeted therapy called SAR439859, which is currently being evaluated in clinical trials for the treatment of advanced breast cancer, including ESR1 mutated metastatic breast cancer. SAR439859 is an oral selective estrogen receptor degrader (SERD) that works by blocking the activity of the estrogen receptor (ER) protein, which is often overexpressed in breast cancer cells. The drug has shown promising results in preclinical studies, and it is currently being evaluated in several clinical trials to assess its safety and efficacy in breast cancer patients.
- G1 Therapeutics has been involved in the development of diagnostic tools to identify ESR1 mutations in breast cancer patients. In 2021, the company announced that it had entered into a collaboration with Guardant Health, a leading precision oncology company, to develop a liquid biopsy test for the detection of ESR1 mutations in circulating tumor DNA (ctDNA) from breast cancer patients.
A Old Full Report Analysis Click Here
Key Segments Profiled:
By Hormonal Therapy:
- Tamoxifen
- Aromatase inhibitors
- Ovarian suppression
- Fulvestrant
- Elacestrant
By Chemotherapy:
- Capecitabine
- Carboplatin
- Cisplatin
- Cyclophosphamide
- Docetaxel
- Others
By Targeted Therapy:
- Monoclonal antibodies
- Small molecule inhibitors
- Tumor-agnostic treatments
- Immunotherapy
- Pembrolizumab
- Dostarlimab
By End User:
- Hospitals
- Clinics
- Research and Academic Institutes
- Diagnostic Centres
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
